Literature DB >> 25100520

A new activity for SAMHD1 in HIV restriction.

Zhiyuan Yang1, Warner C Greene1.   

Abstract

Restriction factors are host cell proteins that inhibit retroviral infection. A new study using mutants of human HIV-1 restriction factor SAMHD1 suggests that it inhibits infection through degradation of viral RNA rather than through its dNTPase activity as previously suggested.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25100520     DOI： 10.1038/nm.3657

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  16 in total

1.  SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.

Authors:  Hanna-Mari Baldauf; Xiaoyu Pan; Elina Erikson; Sarah Schmidt; Waaqo Daddacha; Manja Burggraf; Kristina Schenkova; Ina Ambiel; Guido Wabnitz; Thomas Gramberg; Sylvia Panitz; Egbert Flory; Nathaniel R Landau; Serkan Sertel; Frank Rutsch; Felix Lasitschka; Baek Kim; Renate König; Oliver T Fackler; Oliver T Keppler
Journal:  Nat Med       Date:  2012-11       Impact factor: 53.440

2.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.

Authors:  Hichem Lahouassa; Waaqo Daddacha; Henning Hofmann; Diana Ayinde; Eric C Logue; Loïc Dragin; Nicolin Bloch; Claire Maudet; Matthieu Bertrand; Thomas Gramberg; Gianfranco Pancino; Stéphane Priet; Bruno Canard; Nadine Laguette; Monsef Benkirane; Catherine Transy; Nathaniel R Landau; Baek Kim; Florence Margottin-Goguet
Journal:  Nat Immunol       Date:  2012-02-12       Impact factor: 25.606

3.  The ribonuclease activity of SAMHD1 is required for HIV-1 restriction.

Authors:  Jeongmin Ryoo; Jongsu Choi; Changhoon Oh; Sungchul Kim; Minji Seo; Seok-Young Kim; Daekwan Seo; Jongkyu Kim; Tommy E White; Alberto Brandariz-Nuñez; Felipe Diaz-Griffero; Cheol-Heui Yun; Joseph A Hollenbaugh; Baek Kim; Daehyun Baek; Kwangseog Ahn
Journal:  Nat Med       Date:  2014-07-20       Impact factor: 53.440

4.  Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1.

Authors:  Alexandra Cribier; Benjamin Descours; Ana Luiza Chaves Valadão; Nadine Laguette; Monsef Benkirane
Journal:  Cell Rep       Date:  2013-04-17       Impact factor: 9.423

5.  The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation.

Authors:  Tommy E White; Alberto Brandariz-Nuñez; Jose Carlos Valle-Casuso; Sarah Amie; Laura Anh Nguyen; Baek Kim; Marina Tuzova; Felipe Diaz-Griffero
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

6.  Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-mediated restriction of HIV-1.

Authors:  Henning Hofmann; Thomas D Norton; Megan L Schultz; Sylvie B Polsky; Nicole Sunseri; Nathaniel R Landau
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

7.  Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction.

Authors:  Natalia Beloglazova; Robert Flick; Anatoli Tchigvintsev; Greg Brown; Ana Popovic; Boguslaw Nocek; Alexander F Yakunin
Journal:  J Biol Chem       Date:  2013-01-30       Impact factor: 5.157

8.  HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase.

Authors:  David C Goldstone; Valerie Ennis-Adeniran; Joseph J Hedden; Harriet C T Groom; Gillian I Rice; Evangelos Christodoulou; Philip A Walker; Geoff Kelly; Lesley F Haire; Melvyn W Yap; Luiz Pedro S de Carvalho; Jonathan P Stoye; Yanick J Crow; Ian A Taylor; Michelle Webb
Journal:  Nature       Date:  2011-11-06       Impact factor: 49.962

9.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.

Authors:  Kasia Hrecka; Caili Hao; Magda Gierszewska; Selene K Swanson; Malgorzata Kesik-Brodacka; Smita Srivastava; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  Tetramerization of SAMHD1 is required for biological activity and inhibition of HIV infection.

Authors:  Junpeng Yan; Sarabpreet Kaur; Maria DeLucia; Caili Hao; Jennifer Mehrens; Chuanping Wang; Marcin Golczak; Krzysztof Palczewski; Angela M Gronenborn; Jinwoo Ahn; Jacek Skowronski
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157
View more
  4 in total

1.  Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients.

Authors:  Maura Statzu; Letizia Santinelli; Agnese Viscido; Claudia Pinacchio; Giancarlo Ceccarelli; Claudia Rotondo; Giuseppe Corano Scheri; Ivano Mezzaroma; Ombretta Turriziani; Guido Antonelli; Gabriella d'Ettorre; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2018-12-18       Impact factor: 4.148

2.  Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation.

Authors:  Michela Sabbatucci; Daniela Angela Covino; Cristina Purificato; Alessandra Mallano; Maurizio Federico; Jing Lu; Arturo Ottavio Rinaldi; Matteo Pellegrini; Roberta Bona; Zuleika Michelini; Andrea Cara; Stefano Vella; Sandra Gessani; Mauro Andreotti; Laura Fantuzzi
Journal:  Retrovirology       Date:  2015-01-22       Impact factor: 4.602

3.  Cyclin F/FBXO1 Interacts with HIV-1 Viral Infectivity Factor (Vif) and Restricts Progeny Virion Infectivity by Ubiquitination and Proteasomal Degradation of Vif Protein through SCFcyclin F E3 Ligase Machinery.

Authors:  Tracy Augustine; Priyanka Chaudhary; Kailash Gupta; Sehbanul Islam; Payel Ghosh; Manas Kumar Santra; Debashis Mitra
Journal:  J Biol Chem       Date:  2017-02-09       Impact factor: 5.157

Review 4.  Prospects in Innate Immune Responses as Potential Control Strategies against Non-Primate Lentiviruses.

Authors:  Lorena de Pablo-Maiso; Ana Doménech; Irache Echeverría; Carmen Gómez-Arrebola; Damián de Andrés; Sergio Rosati; Esperanza Gómez-Lucia; Ramsés Reina
Journal:  Viruses       Date:  2018-08-17       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.